within Pharmacolibrary.Drugs.ATC.N;

model N05BA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.02,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Adinazolam is a benzodiazepine derivative that was developed as an anxiolytic and antidepressant. It acts primarily as an anxiolytic agent. Adinazolam is not approved for medical use and is not commonly prescribed today, mainly due to regulatory limitations and lack of widespread clinical adoption.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for a healthy adult as no human clinical PK studies have been published. PK values are inferred from limited preclinical data and similarity to other benzodiazepines (e.g., alprazolam).</p><h4>References</h4><ol><li><p>Fleishaker, JC, &amp; Phillips, JP (1989). Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. <i>Psychopharmacology</i> 99(1) 34–39. DOI:<a href=&quot;https://doi.org/10.1007/BF00634449&quot;>10.1007/BF00634449</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2506603/&quot;>https://pubmed.ncbi.nlm.nih.gov/2506603</a></p></li><li><p>Golden, PL, et al., &amp; Brouwer, KL (1994). Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. <i>Clinical pharmacology and therapeutics</i> 56(2) 133–141. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1994.116&quot;>10.1038/clpt.1994.116</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8062489/&quot;>https://pubmed.ncbi.nlm.nih.gov/8062489</a></p></li><li><p>Fleishaker, JC, et al., &amp; Grahnén, A (1992). Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. <i>Journal of clinical psychopharmacology</i> 12(6) 403–414. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1474178/&quot;>https://pubmed.ncbi.nlm.nih.gov/1474178</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BA07;
